

Haematologica
HAEMATOL/2019/242735
Version 3

Kreuth V initiative: European consensus proposals for treatment of haemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies

Flora Peyvandi, Karin Berger, Rainer Seitz, Anneliese Hilger, Marie-Laure Hecquet, Michael Wierer, Karl-Heinz Buchheit, Brian O Mahony, Amanda Bok, Mike Makris, Ulrich Mansmann, Wolfgang Schramm, and Pier Mannuccio Mannucci

Disclosures: FP reports participation at advisory board of Bioverativ, Roche, Sanofi, Sobi, Takeda and Grifols. KB has received a Research grant from Roche. RS, AH, MLH, MW, KHB, BOM, AB, UM have no competing interests to declare. MM has acted as consultant or participated in advisory panels for Bioverativ, CSL Behring, NovoNordisk and Shire. MM is also the project leader for EUHASS which receives funding from Bayer, Biotest, BPL, CSL Behring, Grifols, Kedrion, LFB, NovoNordisk, Octapharma, Pfizer, Roche, Takeda and Sobi. WS has participated in a DSMB for Biotest and received honoraria for lectures from Biotest, Novo, Roche, Takeda and Bio&Bio. PMM: Member of the scientific board for the Bayer Awards. He has also received honoraria from Bayer, Kedrion and Novo Nordisk for participation at their educational symposia.

Contributions: All authors contributed to the discussion and made the consensus recommendations. Flora Peyvandi wrote the first draft of the manuscript. All other authors made intellectual contributions to, reviewed and approved the final manuscript.